Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Capricor Therapeutics (CAPR – Research Report) and keeping the price target at $25.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Jason McCarthy has given his Buy rating due to a combination of factors surrounding Capricor Therapeutics. The company’s lead candidate, Deramiocel, is advancing in its clinical development for treating Duchenne muscular dystrophy, with recent updates indicating that the FDA has not required an advisory committee meeting, maintaining the priority review status and the PDUFA date. This regulatory clarity has helped the stock recover after a recent decline.
Additionally, the positive long-term data from the HOPE-2 open-label extension study presented at the PPMD conference further supports Deramiocel’s efficacy in preserving cardiac function and slowing skeletal muscle disease progression. The favorable safety profile and the unmet need in addressing cardiac decline in DMD patients enhance the likelihood of approval. The valuation model anticipates a commercial launch in 2026, with adjustments for clinical trial risks and a discount rate applied to derive a 12-month price target of $25.
McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Brainstorm Cell Therapeutics, and Gain Therapeutics. According to TipRanks, McCarthy has an average return of -20.6% and a 27.77% success rate on recommended stocks.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $77.00 price target.